Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? (Q34669820)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

title

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Andrea Anichini

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

6

Francesco M Marincola

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

author name string

Giorgio Parmiani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Chiara Castelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Piero Dalerba

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

Roberta Mortarini

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

publication date

1 June 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

Journal of the National Cancer Institute

9 November 2019

language of work or name

English

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

805-818

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12048268%20AND%20SRC:MED&resulttype=core&format=json

publication type of scholarly work

9 November 2019

review article

1 reference

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

A listing of human tumor antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

MHC restriction in three dimensions: a view of T cell receptor/ligand interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Agonist peptide from a cytotoxic t-lymphocyte epitope of human carcinoembryonic antigen stimulates production of tc1-type cytokines and increases tyrosine phosphorylation more efficiently than cognate peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Structural and functional consequences of altering a peptide MHC anchor residue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Degradation of cell proteins and the generation of MHC class I-presented peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillanc

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Human neoplasms elicit multiple specific immune responses in the autologous host

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Peptide-induced antiviral protection by cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

A mouse mutant p53 product recognized by CD4+ and CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

The makings of a tumor rejection antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

T cell priming versus T cell tolerance induced by synthetic peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Differentiation of T regulatory cells by immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Dendritic cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Heat Shock Proteins Come of Age: Primitive Functions Acquire New Roles in an Adaptive World

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

In vivo tracking of tumor-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Status of activation of circulating vaccine-elicited CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Phenotypic analysis of antigen-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

A natural history of melanoma: serial gene expression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805

CD4 T cells and their role in antitumor immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.11.805